Shandong Cancer Hospital and Institute

• NCT07340515

  Collaborator, Phase 3, Recruiting, 300 people, 14 Jan 2026

• NCT07093931

  Phase 4, Not yet recruiting, 468 people, 30 Jul 2025

• BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + Surgery/SBRT for BCLC-C HCC With PVTT and/or Oligometastases

  Phase 2, Recruiting, 54 people, 14 Jul 2025

• NCT06942416

  Phase 2, Recruiting, 36 people, 24 Apr 2025

• NCT06802757

  Phase 2, Recruiting, 72 people, 31 Jan 2025

• NCT06398405

  Phase 2, Status unknown, 72 people, 3 May 2024

• NCT06356584

  Phase 2, Recruiting, 62 people, 10 Apr 2024

• NCT05900921

  Collaborator, Phase 2, Status unknown, 132 people, 13 Jun 2023

• NCT05323890

  Phase 2, Status unknown, 15 people, 12 Apr 2022

• NCT05099848

  Phase 2, Completed, 21 people, 29 Oct 2021

• NCT04981665

  Collaborator, Phase 2, Status unknown, 50 people, 29 Jul 2021

• NCT04982549

  Phase 2, Status unknown, 35 people, 29 Jul 2021

• NCT04676997

  Phase 2, Status unknown, 20 people, 21 Dec 2020

• NCT04562337

  Phase 2, Status unknown, 67 people, 24 Sept 2020

• NCT04143906

  Phase 2, Status unknown, 200 people, 30 Oct 2019

• NCT03617432

  Collaborator, Phase 2, Status unknown, 114 people, 6 Aug 2018

• NCT02972333

  Phase 3, Status unknown, 150 people, 23 Nov 2016

• NCT02409186

  Phase 3, Status unknown, 200 people, 6 Apr 2015

• NCT01917578

  Phase 3, Status unknown, 4 people, 6 Aug 2013

• NCT01796444

  Phase 3, Withdrawn, 0 people, 21 Feb 2013

Sources: clinicaltrials.gov